Investigating inflammatory markers in glaucoma after corneal transplantation
Uncovering Inflammatory Mediators of Glaucoma Pathogenesis After Corneal Transplantation in Aqueous Humor and Tears
This study is trying to find out if certain markers in the tears and eye fluid of people who have had corneal transplants can help spot early signs of glaucoma.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) Academic / other |
| Locations | 1 site (Montréal, Quebec) |
| Trial ID | NCT04339907 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the role of inflammatory mediators in the aqueous humor and tears of patients who have undergone corneal transplantation, particularly focusing on those with glaucoma. By sampling these fluids, researchers hope to identify potential biomarkers that could indicate early signs of glaucoma development or progression. The study includes various patient groups, including those with and without glaucoma, and those who have had different types of corneal surgeries. The ultimate goal is to better understand the mechanisms behind glaucoma in these patients and improve treatment strategies.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with specific ocular conditions related to glaucoma and corneal transplantation.
Not a fit: Patients under 18 or those with ocular diseases not specified in the study criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and better management of glaucoma in patients who have undergone corneal transplantation.
How similar studies have performed: While the specific approach of using inflammatory biomarkers in this context may be novel, similar studies have shown promise in understanding glaucoma and its progression.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 years old or older * Informed consent * Ability to be followed for the duration of the study * Presence of ocular disease specified for each group Specific criteria for each group: * Group 1 : have no glaucoma and no systemic diseases * Group 2 : need to have glaucoma filtration surgery without prior corneal transplantation * Group 3 : need to have corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis), with or without glaucoma * Group 4 : need to have intraocular surgery after prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis) * Group 5 : need to have glaucoma filtration surgery with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis) Exclusion Criteria: * Aged less than 18 * Inability to give informed consent * Presence of ocular diseases other than those studied herein
Where this trial is running
Montréal, Quebec
- Centre Hospitalier de l'Université de Montréal (CHUM) — Montréal, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Younes Agoumi, MD — Centre hospitalier de l'Université de Montréal (CHUM)
- Study coordinator: Marie-Catherine Tessier, M.Sc.
- Email: marie-catherine.tessier.chum@ssss.gouv.qc.ca
- Phone: 1-514-890-8000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.